Akebia Therapeutics (AKBA) Return on Capital Employed (2014 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Return on Capital Employed of 2.7% for Q1 2026, up 1535.0% year-over-year from 0.17% in Q1 2025, and down 76.14% quarter-over-quarter from 11.33% in Q4 2025.
Akebia Therapeutics (AKBA) Return on Capital Employed (2014 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Return on Capital Employed for 13 consecutive years, with 2.7% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1535.0% year-over-year to 2.7%; the TTM figure through Mar 2026 stood at 2.7% (up 1535.0% YoY), while the FY2025 annual figure was 17.32%, up 5091.0% from the prior year.
- Return on Capital Employed retreated to 2.7% in Q1 2026 per AKBA's latest filing, from 11.33% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 11.33% in Q4 2025 and bottomed at 93.53% in Q1 2022.
- Historically, Return on Capital Employed has averaged 27.1% across 5 years, with a median of 29.85% in 2022.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 1110 bps — and 2023, when it surged 7326 bps.
- Akebia Therapeutics' Return on Capital Employed stood at 29.85% in 2022, then retreated by 12 bps to 33.4% in 2023, then declined by 14 bps to 37.95% in 2024, then surged by 130 bps to 11.33% in 2025, then sank by 76 bps to 2.7% in 2026.
- Business Quant data shows AKBA's Return on Capital Employed at 2.7% in Q1 2026, 11.33% in Q4 2025, and 8.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Akebia Therapeutics | 247.60 Mn | 92.06 Mn | 38.70 Mn | -7.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.75% |
| Mar 31, 2026 | 2.70% |
| Dec 31, 2025 | 11.33% |
| Sep 30, 2025 | 8.01% |
| Jun 30, 2025 | 0.38% |
| Mar 31, 2025 | -12.64% |
| Dec 31, 2024 | -37.95% |
| Sep 30, 2024 | -23.51% |
| Jun 30, 2024 | -30.57% |
| Mar 31, 2024 | -21.30% |
| Dec 31, 2023 | -33.40% |
| Sep 30, 2023 | -31.88% |
| Jun 30, 2023 | -51.31% |
| Mar 31, 2023 | -20.27% |
| Dec 31, 2022 | -29.85% |
| Sep 30, 2022 | -48.05% |
| Jun 30, 2022 | -48.83% |
| Mar 31, 2022 | -93.53% |
| Dec 31, 2021 | -86.79% |
| Sep 30, 2021 | -68.10% |